Neopterin as a Biomarker in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension | Zendy

Anna Smukowska-Gorynia | Zendy; Justyna Marcinkowska | Zendy; Ewa Chmara | Zendy; Katarzyna Małaczyńska-Rajpold | Zendy; Sylwia Sławek-Szmyt | Zendy; Artur Cieślewicz | Zendy; Magdalena Janus | Zendy; Aleksander Araszkiewicz | Zendy; Stanisław Jankiewicz | Zendy; Anna Komosa | Zendy; Anna OlasińskaWiśniewska | Zendy; Iga Tomaszewska | Zendy; Tatiana MularekKubzdela | Zendy

Open Access

Neopterin as a Biomarker in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

Author(s) -

Anna Smukowska-Gorynia,

Justyna Marcinkowska,

Ewa Chmara,

Katarzyna Małaczyńska-Rajpold,

Sylwia Sławek-Szmyt,

Artur Cieślewicz,

Magdalena Janus,

Aleksander Araszkiewicz,

Stanisław Jankiewicz,

Anna Komosa,

Anna OlasińskaWiśniewska,

Iga Tomaszewska,

Tatiana MularekKubzdela

Publication year - 2018

Publication title -

respiration

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.264

H-Index - 81

eISSN - 1423-0356

pISSN - 0025-7931

DOI - 10.1159/000488908

Subject(s) - medicine , chronic thromboembolic pulmonary hypertension , neopterin , pulmonary hypertension , cardiology , biomarker , intensive care medicine , biochemistry , chemistry

Upregulation of the immune system is regarded to play an important role in the etiopathobiology of pulmonary arterial hypertension (PAH) and inoperable chronic thromboembolic pulmonary hypertension (CTEPH). To the best of our knowledge, neopterin (NP) has never been investigated in patients with PAH and CTEPH.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research